

Steroids

Steroids 64 (1999) 844-848

Synthesis of (25*R*)-26-hydroxy-15-ketosterols☆

Hong-Seok Kim*, Dong-Il Kim¹

Department of Industrial Chemistry, Kyungpook National University, 1370 Sankyuk-dong, Pook-Ku, Taegu 702-701, South Korea

Received 9 November 1998; received in revised form 30 April 1999; accepted 5 May 1999

Abstract

(25R)-3 β ,26-Dihydroxy-5 α -cholest-8(14)-en-15-one (1) and (25R)-3 β ,26-dihydroxy-5 α ,14 β -cholest-16-en-15-one (2) were synthesized from (25R)-3 β ,26-dibenzoyloxy-5 α ,14 α -cholest-16-ene (4). Oxidation of 4 with CrO₃-3,5-dimethylpyrazole at -20° C gave (25R)-3 β ,26-dibenzoyloxy-5 α ,14 α -cholest-16-en-15-one (5) along with (25R)-3 β ,26-dibenzoyloxy-5 α -cholest-16 α ,17 α -epoxide (6). Oxidation of 5 with selenium dioxide afforded (25R)-3 β ,26-dibenzoyloxy-5 α -cholest-8(14),16-dien-15-one (7) and (25R)-3 β ,26-dibenzoyloxy-5 α ,14 β -cholest-16-en-15-one (8). Selective hydrogenation of 7 followed by hydrolysis in alcoholic potassium hydroxide yielded (25R)-3 β ,26-dihydroxy-5 α ,14 β -cholest-16-en-15-one (1). Hydrolysis of 5 and 8 in alcoholic potassium hydroxide provided (25R)-3 β ,26-dihydroxy-5 α ,14 β -cholest-16-en-15-one (2). © 1999 Elsevier Science Inc. All rights reserved.

Keywords: 15-Ketosterol; Allylic oxidation; Selenium dioxide; Selective hydrogenation; Hydrolysis

1. Introduction

(25R)-3 β ,26-Dihydroxy-5 α -cholest-8(14)-en-15-one (1) has been shown to be a major metabolite of 3β -hydroxy- 5α -cholest-8(14)-en-15-one (3) after incubation with rat liver mitochondria [1,2] (Fig. 1). Thus, 1, a major mitochondrial metabolite of 3, was found to be highly active in the suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cultured mammalian cells and in inhibiting oleoyl coenzyme A-dependent esterification of cholesterol in jejunal microsomes [2]. In continuation of our interest in the synthesis of 15-ketosterols, we investigated an alternative synthesis of **1**. Although compound **1** has already been synthesized from 3β ,26-dibenzoyloxy- 5α -cholest-8(14)ene^[2] and 3 β ,26-diacetoxy-5 α -cholest-8,14-diene^[3], this compound and its analog 2 are needed for biological evaluation. Herein, we wish to report the synthesis of two (25R)-26-hydroxy-15-ketosterols, 1 and 2, from the same starting material, 4. Sterol 2 shows close structural similarity to **1**, the difference lying in the position of the double bond.

2. Experimental

Melting points were measured by using a Thomas-Hoover (Thomas Scientific, USA) melting point apparatus and are uncorrected. IR spectra were recorded on a Matton GL-6030E spectrophotometer. Ultraviolet (UV) spectra were determined in methanol on a Shimadzu (Shimadzu Scientific Instrument, Kyoto, Japan) UV-2100 spectrophotometer. ¹H and ¹³C NMR spectra were recorded on a Bruker AM-300 instrument (Bruker, Billerica, MA, USA); unless otherwise stated, all NMR were performed in CDCl₃ solution. The chemical shifts of ¹H NMR spectra are given in ppm downfield from tetramethylsilane, and ¹³C NMR spectra were referenced to CDCl₃ at 77.0 ppm. ¹H and ¹³C NMR assignments were made from distortionless enhancement by polarization (DEPT), ¹H-¹H shift-correlated 2D NMR (COSY), ¹³C-¹H shift-correlated 2D NMR (HETCOR), and by comparison with spectra of similar sterols [2,3]. Lowresolution MS were recorded on a Shimadzu QP-1000 spectrometer with electron energy of 70 eV and direct sample introduction. High-resolution MS were measured on a JEOL KMS-DX 303 spectrometer. Elemental anal-

^{*} Corresponding author. Tel.: +82-53-950-5588; fax: +82-53-950-6594.

E-mail address: kimhs@kyungpook.ac.kr (H.-S. Kim)

[☆]Dedicated to the memory of Prof. George J. Schroepfer Jr., who died December 11, 1998.

¹ Present address: Household & Personal Care Products R&D Institute, LG Chem./Research Park (W), Taejon, Korea.

⁰⁰³⁹⁻¹²⁸X/99/ – see front matter © 1999 Elsevier Science Inc. All rights reserved. PII: S0039-128X(99)00065-3



Fig. 1. Structures of 3β , 26-dihydroxy- 5α -cholest-8(14)-en-15-one (1), 3β , 26-dihydroxy- 5α , 14β -cholest-16-en-15-one (2), and 3β -hydroxy- 5α -cholest-8(14)-en-15-one (3).

yses were performed by CSI at Kyungpook National University. TLC analyses were performed on precoated 0.2 mm HPTLC silica gel 60 plates (Merck, Darmstadt, Germany); substances were visualized by spraying with 5% ammonium molybdate in 10% H_2SO_4 followed by heating. Radial chromatography was performed on a Harrison chromatotron (Harrison Research, Palo Alto, CA, USA), by using Merck silica gel 60 PF₂₅₄. For routine column chromatography, Merck silica gel (70-230 mesh) was used as an adsorbent. Solvents were distilled before use and were dried, as necessary, by procedures in the literature [4]. Solutions were dried over anhydrous sodium sulfate. 3,5-Dimethylpyrazole (3,5-DMP), CrO₃, imidazole, and SeO₂ were purchased from Aldrich (Milwaukee, WI, USA) and used as received. Preparation of (25R)-3 β ,26-dibenzoyloxy-5 α -cholest-16-ene **4** will be described elsewhere.

2.1. (25R)-3β,26-Dibenzoyloxy-5α,14α-cholest-16-en-15one (5)

3,5-Dimethylpyrazole (1.34 g, 13.97 mmol) was added to a suspension of chromium trioxide (1.40 g, 13.97 mmol) in dry CH_2Cl_2 (5 ml) at $-20^{\circ}C$ under nitrogen, and the resulting mixture was stirred at -20° C for 30 min. A solution of 4 (300 mg, 0.49 mmol) in dry CH₂Cl₂ (2 ml) was added to the dark red solution. The resulting mixture was stirred at -20°C for 1 h. A 5 N sodium hydroxide solution (2 ml) was subsequently added to the reaction mixture and stirred at 0°C for 30 min. The resulting mixture was extracted twice with ethyl acetate (30 ml), and the extracts were washed sequentially with 10% HCl and water and then dried. The solvent was evaporated, and the crude product was chromatographed on silica gel (ethyl acetate/hexane 5:95, v/v). The first fraction gave (25R)-3 β ,26-dibenzoyloxy-5 α ,14 α -cholest-16 α ,17 α -epoxide (6) (76 mg, 0.12 mmol, 24%). m.p. 120.5-121.5°C (dichloromethane-methanol). Single component on TLC in two solvent systems: $R_{\rm f}$ 0.63 (ethyl acetate/hexane 1:4), 0.43 (ethyl acetate/hexane 1:9). FT-IR (KBr): 2937, 2859, 1717, 1454, 1273, 1111, 714 cm⁻¹; ¹H NMR: δ 8.03 (2H, m, *o* of Ph), 7.25–7.57 (3H, m, m, p of Ph), 4.93 (1H, m, 3α -H), 4.19 (1H, dd, J =10.7, 6.0 Hz, 26-H_a), 4.12 (1H, dd, J = 10.7, 6.5 Hz, 26-H_b), 3.25 (1H, s, 16 β -H), 1.013 (3H, d, J = 6.8 Hz, $21-CH_3$, 0.908 (3H, d, J = 6.8 Hz, $27-CH_3$), 0.874 (3H, s, 18-CH₃), 0.778 (3H, s, 19-CH₃); ¹³C NMR: δ 166.6 and 166.0 (C = O), 132.8 and 132.6 (C4 of Ph), 131.0 and 130.5 (C1 of Ph), 129.5 (C2 of Ph), 128.3 and 128.2 (C3 of Ph), 74.2 (C-3), 73.4 (C-17), 69.7 (C-26), 60.0 (C-16), 54.6 (C-9), 45.0 (C-14), 44.8 (C-5), 42.6 (C-13), 36.7 (C-11), 35.7 (C-10), 35.7 (C-1), 34.1 (C-8), 33.9 (C-22), 33.7 (C-4), 33.5 (C-24), 33.0 (C-25), 31.6 (C-15), 29.2 (C-20), 28.5 (C-7), 27.5 (C-6), 27.4 (C-2), 24.9 (C-23), 20.9 (C-11), 17.0 (C-21), 16.9 (C-27), 16.1 (C-18), 12.2 (C-19); MS *m/z*: 626 (38, M⁺), 611 (6, M-CH₃), 608 (5, M-H₂O), 504 (23, M-C₆H₅CO₂H), 489 (11, M-C₆H₅CO₂H-CH₃), 486 (8, M-C₆H₅CO₂H-H₂O), 393 (79, M-SC), 367 (10, M-2C₆H₅CO₂H-CH₃), 271 (16, M-SC-C₆H₅CO₂H), 253 (11, M-SC-C₆H₅CO₂H-H₂O); high-resolution MS m/z: 626.4004 for C₄₁H₅₄O₅ requires 626.3971. Anal. Calcd for C₄₁H₅₄O₅: C, 78.56; H, 8.68; Found C, 78.40; H, 8.72.

Further elution with the same solvent gave 5 (148 mg, 0.24 mmol, 49%) as a white solid. m.p. 49.5-50.5°C (dichloromethane-methanol). Single component on TLC in two solvent systems: R_f 0.45 (ethyl acetate/hexane 1:4), 0.24 (ethyl acetate/hexane 1:9). FT-IR (KBr): 2937, 2859, 1713, 1455, 1273, 1107, 710 cm⁻¹; ¹H NMR: δ 8.03 (2H, m, o of Ph), 7.26-7.57 (3H, m, m, p of Ph), 5.62 (1H, s, 16-H), 4.95 (1H, m, 3α -H), 4.19 (1H, dd, J =10.5, 6.0 Hz, 26-H_a), 4.12 (1H, dd, J = 10.5, 6.5 Hz, 26-H_b), 2.74 (1H, d, J = 12.9 Hz, 7 β -H), 2.42 (1H, q, J =6.8 Hz, 20-H), 1.105 (3H, d, J = 6.7 Hz, 21-CH₃), 1.009 $(3H, d, J = 6.8 \text{ Hz}, 27\text{-}CH_3), 0.993 (3H, s, 18\text{-}CH_3),$ 0.927 (3H, s, 19-CH₃); ¹³C NMR: δ 207.5 (C-15), 188.3 (C-17), 166.5 and 166.0 (C = O), 132.8 and 132.6 (C4 of Ph), 130.9 and 130.5 (C1 of Ph), 129.5 (C2 of Ph), 128.3 and 128.2 (C3 of Ph), 124.4 (C-16), 74.0 (C-3), 69.6 (C-26), 63.8 (C-14), 54.9 (C-9), 47.0 (C-13), 44.9 (C-5), 36.6 (C-12), 36.2 (C-1), 35.9 (C-10), 34.0 (C-4), 33.5 (C-24), 33.1 (C-8), 32.7 (C-22), 32.6 (C-25), 32.4 (C-20), 30.4 (C-7), 28.2 (C-6), 27.5 (C-2), 24.9 (C-23), 23.6 (C-21), 21.2 (C-18), 20.5 (C-11), 16.9 (C-27), 12.3 (C-19); UV λ_{max} : 229 nm (log ϵ 4.19); MS *m/z*: 624 (65, M⁺), 609 (9, M-CH₃), 606 (2, M-H₂O), 502 (53, M-C₆H₅CO₂H), 487 (10, M-C₆H₅CO₂H-CH₃), 484 (2, M-C₆H₅CO₂H-H₂O), 391 (6, M-SC), 365 (4, M-2C₆H₅CO₂H-CH₃), 269 (13, M-SC-C₆H₅CO₂H), 251 (3, M-SC-C₆H₅CO₂H-H₂O); highresolution MS m/z: 624.3792 for C₄₁H₅₂O₅ requires 624.3814. Anal. Calcd for C₄₁H₅₂O₅: C, 78.81; H, 8.39; Found C, 78.54; H, 8.30.

2.2. (25R)-3β,26-Dibenzoyloxy-5α-cholest-8(14),16-dien-15-one (7)

A mixture of 5 (98 mg, 0.157 mmol) and selenium oxide (87 mg, 0.78 mmol) in 2-methyl-2-propanol (5 ml) was refluxed for 5 h under nitrogen. After removal of insoluble material by filtration through a pad of celite, the filtrate was diluted with water (20 ml) and extracted with ethyl acetate (30 ml). The combined extracts were washed with brine, dried, and concentrated to give a yellow residue (109 mg). The crude product was chromatographed on silica gel (ethyl acetate/hexane 1:4). The first fraction gave 3β .26-dibenzoyloxy- 5α , 14 β -cholest-16-en-15-one (8) (22 mg, 0.035 mmol, 22%) as a viscous oil. Single component on TLC in two solvent systems: $R_{\rm f}$ 0.41 (ethyl acetate/hexane 1:4), 0.24 (ethyl acetate/hexane 1:9). IR (neat): 2933, 2867, 1717, 1609, 1455, 1316, 1273, 1111, 713 cm⁻¹; ¹H NMR: δ 8.03 (2H, m, o of Ph), 7.26-7.58 (3H, m, m, p of Ph), 5.93 (1H, 16-H), 4.92 (1H, m, 3α -H), 4.19 (1H, dd, J = 10.7, 6.0 Hz, 26-H_a), 4.11 (1H, dd, J = 10.7, 6.4 Hz, 26-H_b), 2.36 (1H, q, J = 6.6 Hz, 20-H), 2.33 (1H, 7 β -H), 1.181 (3H, s, 18-CH₃), 1.106 (3H, d, J = 6.7 Hz, 21-CH₃), 1.016 (3H, d, J = 6.8Hz, 27-CH₃), 0.839 (3H, s, 19-CH₃); ¹³C NMR: δ 210.3 (C-15), 191.6 (C-17), 166.6 and 166.0 (C=O), 132.8 and 132.6 (C4 of Ph), 131.0 and 130.5 (C1 of Ph), 129.5 (C2 of Ph), 128.5 (C-16), 128.3 and 128.2 (C3 of Ph), 74.2 (C-3), 69.7 (C-26), 57.2 (C-14), 48.4 (C-13), 44.6 (C-5), 44.0 (C-9), 38.1 (C-12), 36.8 (C-10), 36.1 (C-1), 34.0 (C-8), 34.0 (C-4), 33.9 (C-22), 33.5 (C-24), 32.7 (C-25), 32.6 (C-20), 29.7 (C-6), 28.9 (C-7), 27.2 (C-2), 24.9 (C-23), 24.3 (C-18), 21.1 (C-21), 19.2 (C-11), 16.9 (C-27), 10.9 (C-19); MS m/z: 624 (3, M^+), 502 (17, $M-C_6H_5CO_2H$), 487 (6, $M-C_6H_5CO_2H-CH_3),$ 391 (3, M-SC), 365 (2,M-2C₆H₅CO₂H-CH₃), 269 (8, M-SC-C₆H₅CO₂H), 251 (2, M-SC-C₆H₅CO₂H-H₂O), 105 (100); high-resolution MS m/z: 624.3841 for C₄₁H₅₂O₅ requires 624.3814.

Further elution with the same solvent gave 7 (44 mg, 0.071 mmol, 45%) as a white solid. m.p. 158-159°C (dichloromethane-methanol). Single component on TLC in two solvent systems: $R_{\rm f}$ 0.38 (ethyl acetate/hexane 1:4), 0.16 (ethyl acetate/hexane 1:9). FT-IR (KBr): 2944, 2867, 1717, 1679, 1636, 1601, 1451, 1316, 1277, 1176, 1111, 714 cm⁻¹; ¹H NMR: δ 8.03 (2H, m, o of Ph), 7.26–7.58 (3H, m, *m*, *p* of Ph), 5.93 (1H, 16-H), 5.00 (1H, m, 3α-H), 4.19 (1H, dd, J = 10.7, 5.9 Hz, 26-H_a), 4.12 (1H, dd, J = 10.7, 6.3 Hz, 26-H_b), 4.08 (1H, dd, J = 9.9, 2.0 Hz, 7 β -H), 2.39 (1H, q, J = 6.8 Hz, 20-H), 1.155 (3H, s, 18-CH₃), 1.102 (3H, d, J =6.8 Hz, 21-CH₃), 1.013 (3H, d, J = 6.8 Hz, 27-CH₃), 0.856 (3H, s, 19-CH₃); ¹³C NMR: δ 197.3 (C-15), 186.5 (C-17), 166.6 and 166.0 (C=O), 145.2 (C-8), 137.9 (C-14), 132.8 and 132.7 (C4 of Ph), 130.8 and 130.5 (C1 of Ph), 129.5 (C2 of Ph), 128.3 and 128.2 (C3 of Ph), 127.5 (C-16), 73.8 (C-3), 69.7 (C-26), 51.2 (C-9), 45.4 (C-13), 44.4 (C-5), 38.9 (C-10), 37.0 (C-12), 36.2 (C-1), 33.7 (C-4), 33.7 (C-22), 33.5 (C-24), 32.8 (C-25), 32.6 (C-20), 30.5 (C-7), 29.3 (C-6), 27.4 (C-2), 25.0 (C-23), 24.8 (C-21), 21.7 (C-18),

19.7 (C-11), 16.9 (C-27), 12.8 (C-19); UV λ_{max} : 203 nm (log ϵ 4.26), 229 nm (log ϵ 4.49), 265 nm (log ϵ 4.23); MS m/z: 622 (100, M⁺), 607 (3, M-CH₃), 500 (21, M-C₆H₅CO₂H), 485 (12, M-C₆H₅CO₂H-CH₃), 389 (4, M-SC), 363 (3, M-2C₆H₅CO₂H-CH₃), 267 (6, M-SC-C₆H₅CO₂H); high-resolution MS m/z: 622.3682 for C₄₁H₅₀O₅ requires 622.3658. Anal. Calcd for C₄₁H₅₀O₅: C, 79.07; H, 8.09; Found C, 79.46; H, 8.21.

2.3. (25R)-3β,26-Dibenzoyloxy-5α-cholest-8(14)-en-15one (**9**)

Compound 7 (50 mg, 0.080 mmol) was dissolved in ethyl acetate (5 ml) and hydrogenated at 1 atmosphere of H₂ at room temperature for 3 h in the presence of 5% Pt/C (25 mg). After removal of insoluble material by filtration through a short pad of celite, the solvent was evaporated to give a solid, which was chromatographed on silica gel (ethyl acetate/hexane 1:5) and yielded a white solid 9 (36 mg, 0.058 mmol, 73%). m.p. 165-166°C (dichloromethanemethanol). Single component on TLC in two solvent systems: $R_{\rm f}$ 0.52 (ethyl acetate/hexane 1:4), 0.32 (ethyl acetate/ hexane 1:9). FT-IR (KBr): 2937, 2871, 1713, 1621, 1455, 1277, 1176, 1115, 714 cm⁻¹; ¹H NMR: δ 8.03 (2H, m, *o* of Ph), 7.26–7.58 (3H, m, m, p of Ph), 4.99 (1H, m, 3α-H), 4.21 (1H, dd, J = 10.7, 5.9 Hz, 26-H_a), 4.12 (1H, dd, J =10.7, 6.5 Hz, 26-H_b), 4.15 (1H, d, J = 16.4 Hz, 7 β -H), 1.021 (3H, d, J = 6.6 Hz, 21-CH₃), 1.013 (3H, d, J = 6.7Hz, 27-CH₃), 0.983 (3H, s, 18-CH₃), 0.784 (3H, s, 19-CH₃); ¹³C NMR: δ 207.8 (C-15), 166.6 and 166.1 (C=O), 150.2 (C-8), 140.4 (C-14), 132.8 and 132.7 (C4 of Ph), 130.8 and 130.5 (C1 of Ph), 129.5 (C2 of Ph), 128.3 and 128.2 (C3 of Ph), 73.8 (C-3), 69.8 (C-26), 50.9 (C-9), 50.8 (C-17), 44.1 (C-5), 42.6 (C-13), 42.4 (C-16), 38.8 (C-10), 37.0 (C-12), 36.4 (C-1), 35.8 (C-22), 34.5 (C-20), 33.9 (C-4), 33.8 (C-24), 32.7 (C-25), 29.1 (C-6), 27.6 (C-7), 27.4 (C-2), 23.2 (C-23), 19.6 (C-11), 19.2 (C-21), 18.8 (C-18), 17.0 (C-27), 12.9 (C-19); UV λ_{max} : 202 nm (log ϵ 4.14), 229 nm (log ϵ 4.47), 259 nm (log ϵ 4.25); MS m/z: 624 (100, M⁺), 609 (2, M-CH₃), 606 (5, M-H₂O), 502 (22, M-C₆H₅CO₂H), 487 (13, M-C₆H₅CO₂H-CH₃), 484 (3, M-C₆H₅CO₂H-H₂O), 391 (2, M-SC), 365 (9, M-2C₆H₅CO₂H-CH₃), 269 (4, M-SC-C₆H₅CO₂H), 251 (10, M-SC-C₆H₅CO₂H-H₂O); high-resolution MS m/z: 624.3843 for C41H52O5 requires 624.3814. Anal. Calcd for C₄₁H₅₂O₅: C, 78.81; H, 8.39; Found C, 78.80; H, 8.30.

2.4. (25R)-3β,26-Dihydroxy-5α-cholest-8(14)-en-15-one (1)

Compound **9** (118 mg, 0.189 mmol) in 1 M 95% ethanolic potassium hydroxide solution (10 ml) was refluxed for 10 min. The reaction mixture was diluted with water (30 ml) and then extracted with chloroform (30 ml). The combined extracts were washed sequentially with 2% HCl and water, dried, and concentrated to give a solid residue (75 mg), which was further purified with chromatotron (1 mm thick disk, ethyl acetate/hexane 3:7) and afforded a white solid **1** (71 mg, 0.171 mmol, 90%). m.p. 197–198°C (H₂O-methanol) (lit. [2] 197–198°C). Single component on TLC in three solvent systems: R_f 0.30 (ethyl acetate/hexane 1:1), 0.22 (ethyl acetate/hexane/chloroform 4:3:3), 0.25 (diethyl ether/benzene 1:1); MS m/z: 416 (100, M); high-resolution MS m/z: 416.3318 for C₂₇H₄₄O₃ requires 416.3290.

2.5. (25R)-3β,26-Dihydroxy-5α,14β-cholest-16-en-15-one (2)

Compound 5 (39 mg, 0.063 mmol) in 1 M 95% ethanolic potassium hydroxide solution (5 ml) was refluxed for 10 min. The reaction mixture was diluted with water (20 ml) and then extracted with ethyl acetate (20 ml). The combined extracts were washed sequentially with 2% HCl and water, dried, and concentrated to give a viscous residue, which was further purified with chromatotron (1 mm thick disk, ethyl acetate/hexane 1:2) and afforded a viscous oil 2 (25 mg, 0.060 mmol, 95%). Single component on TLC in two solvent systems: R_f 0.40 (ethyl acetate/hexane 2:1), 0.15 (diethyl ether/benzene 3:1). FT-IR (CHCl₃): 3401, 2937, 1685, 1453, 1376, 1268, 1051 cm⁻¹; ¹H NMR: δ 5.92 (1H, s, 16-H), 3.55 (1H, m, 3α -H), 3.47 (1H, dd, J = 10.5, 6.0 Hz, $26-H_a$, 3.40 (1H, dd, J = 10.5, 6.3 Hz, 26-H_b), 1.184 (3H, s, 18-CH₃), 1.095 (3H, d, J = 6.8 Hz, 21-CH₃), 0.901 (3H, d, J = 6.6 Hz, 27-CH₂), 0.769 (3H, s, 19-CH₂); ¹³C NMR: δ 211.1 (C-15), 192.4 (C-17), 128.2 (C-16), 70.1 (C-3), 68.0 (C-26), 57.1 (C-14), 48.3 (C-13), 44.5 (C-5), 44.0 (C-9), 38.0 (C-12), 37.9 (C-4), 36.7 (C-10), 36.6 (C-22), 36.1 (C-1), 35.5 (C-25), 33.8 (C-8), 33.1 (C-24), 32.3 (C-20), 30.8 (C-2), 29.6 (C-6), 28.9 (C-7), 24.9 (C-23), 24.3 (C-18), 20.9 (C-21), 19.0 (C-11), 16.5 (C-27), 10.8 (C-19); MS m/z: 416 (4, M⁺), 288 (100, M-SC), 269 (13), 105 (22), 91 (25), 69 (51), 55 (55); high-resolution MS m/z: 416.3287 for $C_{27}H_{44}O_3$ requires 416.3290.

Compound 8 (12 mg, 0.019 mmol) in 1 M 95% ethanolic potassium hydroxide solution (3 ml) when reacted similarly provided 2 (6.4 mg, 0.015 mmol, 79%) as a viscous oil.

3. Results and discussion

Our interest in the side chain (25R)-26-hydroxy group in compound **1** and **2** led us to choose (25R)-3 β ,26-dibenzoyloxy-5 α -cholest-16-ene **4** as our starting compound. This compound has a quite similar, yet slightly modified structure compared with **1** and **2**. The synthesis of **1** and **2** involved the Clemmensen reduction of diosgenin, hydrogenation of Δ^5 of the resulting cholest-5-ene-3 β ,16 β ,26-triol, selective protection of the 3 β ,26-hydroxyl groups, and the elimination of the 16-hydroxyl group [5]. The resulting compound, in turn, may be transformed to our target molecule by introduction of the required functionality in the C and D rings via allylic oxidation of Δ^{16} .

The synthesis of 1 described in this report is based on the well-established synthesis of the parent 15-ketosterol **3** from 5α -cholest-16-ene [6,7]. This route consists of allylic oxidation to Δ^{16} -15-one, formation of the $\Delta^{8(14),16}$ -15-one, selective hydrogenation of Δ^{16} , and hydrolysis to the desired 15-ketosterol (Scheme 1). Thus, allylic oxidation of the



Scheme 1. Synthetic scheme for the preparation of 3β ,26-dihydroxy- 5α -cholest-8(14)-en-15-one (1) and 3β ,26-dihydroxy- 5α ,14 β -cholest-16-en-15-one (2).

 5α -Δ¹⁶ **4** with CrO₃-3,5-dimethylpyrazole in dichloromethane at -20°C gave a white solid 14α -Δ¹⁶-15-one **5** along with the 16α ,17 α -epoxide **6** in a 2:1 ratio. Compound **5** shows IR (1713 cm⁻¹) and UV [λ_{max} 229 nm (log ϵ 4.19)] absorptions characteristic of Δ¹⁶-15-one functionality. Due to the deshielding by the carbonyl group at the 15 position, the ¹H NMR signal of 7 β -H appears at δ 2.74.

Selenium dioxide oxidation of $14\alpha - \Delta^{16}$ -15-one **5** in 2-methyl-2-propanol yielded products that were a mixture of $\Delta^{8(14),16}$ -15-one **7** (45%) and a viscous oil $14\beta - \Delta^{16}$ -15one **7** (22%), which were isolated by silica gel chromatography. Oxidized compound **5** was easily isomerized to **8**. The 14-H configurations of compounds **5** and **8** were determined based on ¹³C NMR data: i.e. the chemical shift of 18-CH₃ for **5** was at δ 21.2, and that for **8** was at δ 24.3. These values are in good agreement with those reported for the corresponding compound [6,7]. Some characteristic features of compound **7** included the appearance of infrared stretching bands at 1679 and 1636 cm⁻¹ for the conjugated carbonyl group as well as the ¹³C NMR peaks at δ 197.3, 186.5, 145.2, 137.9, and 127.5 assignable to C-15, 17, 8, 14, and 16 atoms, respectively. The addition of the double bond in **7** was confirmed by the bathochromic shift found in **7** (λ_{max} 265 nm; log ϵ 4.23) compared with that in **5** (λ_{max} 229 nm; log ϵ 4.19).

Catalytic hydrogenation of $\Delta^{8(14),16}$ -15-one **7** with 5% platinum on carbon under one atmospheric pressure of hydrogen resulted in $\Delta^{8(14)}$ -15-one **9** in 73% yield. Confirmation of the 17-H configuration of the latter was made by comparing the ¹³C NMR spectrum with that of the value reported in the literature [6,7]. The hydrogenation preferentially took place in the less-hindered α -direction. Various spectroscopic data were consistent with the structure of **9**. For instance, ¹H NMR showed one deshielded 7 β -proton at δ 4.15, and two olefinic carbons appeared at δ 140.4 (C-14) and 150.2 (C-8) on ¹³C NMR spectrum. The absorption at 259 nm (log ϵ 4.25) confirms the existence of $\Delta^{8(14)}$ -15-one. The mass spectrum also revealed a peak at *m/z* 624 corresponding to the molecular ion.

Hydrolysis of **9** in 1 M ethanolic potassium hydroxide solution gave 3β ,26-dihydroxy- 5α -cholest-8(14)-en-15-one **1** in 90% yield. The structure and stereochemistry of **1** were confirmed by comparing the ¹H, ¹³C NMR, and MS values reported in the literature [2,3].

To obtain (25R)- 3β ,26-dihydroxy- 5α ,14 α -cholest-16en-15-one, compound **5** was hydrolyzed in 1 M ethanolic potassium hydroxide solution giving (25R)- 3β ,26-dihydroxy- 5α ,14 β -cholest-16-en-15-one (**2**) in 95% yield. Under basic conditions, 14 α -H in **5** easily epimerized to 14 β -H. Confirmation of the 14 β configuration of **2** was made by comparing the ¹³C NMR spectrum with that of compound **8**. The chemical shifts of 18-CH₃ for both **2** and **8** appeared at exactly same position, δ 24.3. Compound **2** also was prepared by hydrolysis of **8** under same conditions as for **5** in 73% yield. In summary, in this work, we prepared two (25R)-26-hydroxy-15-ketosterols. Studies on the biologic activities of 1 and 2 are now in progress.

Acknowledgment

This work was supported by the Center for Biofunctional Molecules.

References

- [1] Schroepfer GJ Jr, Kim HS, Vermilion JL, Stephens TW, Pinkerton FD, Needleman DK, Wilson WK, St. Pyrek J. Enzymatic formation and chemical synthesis of an active metabolite of 3β-hydroxy-5α-cholest-8(14)-en-15-one, a potent regulator of cholesterol metabolism. Biochem Biophys Res Commun 1988;151:130-6.
- [2] Kim HS, Wilson WK, Needleman DH, Pinkerton FD, Wilson DK, Quiocho FA, Schroepfer GJ Jr. Inhibitors of sterol synthesis: chemical synthesis, structure, and biological activities of (25*R*)-3β,26dihydroxy-5α-cholest-8(14)-en-15-one. J Lipid Res 1989;30:247–61.
- [3] Siddiqui AU, Wilson WK, Schroepfer GJ Jr. Inhibitors of sterol synthesis: an improved chemical synthesis of 26-oxygenated Δ⁸⁽¹⁴⁾-15-ketosterols having the 25*R* configuration. Chem Phys Lipids 1994; 71:202–18.
- [4] Perrin DD, Armarego WLF. Purification of Laboratory Chemicals, 3rd Ed. Oxford: Pergamon Press, 1988.
- [5] Kim DI. Studies on the synthesis of cholesterol lowering agent. M.S. Thesis. Taegu, South Korea: Kyungpook National University, 1993.
- [6] Kim HS, Oh SH. Chemical synthesis of 15-ketosterols. Bioorg Med Chem Lett 1993;3:1339–42.
- [7] Kim HS, Oh SH, Kim DI, Kim IC, Cho KH, Park YB. Chemical synthesis of 15-ketosterols and their inhibitions of cholesteryl ester transfer protein. Bioorg Med Chem 1995;3:367–74.